| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 58 | 2022 | 4795 | 2.320 |
Why?
|
| RNA, Small Interfering | 27 | 2021 | 2197 | 1.660 |
Why?
|
| MicroRNAs | 20 | 2022 | 2887 | 1.310 |
Why?
|
| Neovascularization, Pathologic | 20 | 2021 | 1586 | 1.230 |
Why?
|
| Receptor, EphA2 | 9 | 2024 | 138 | 1.200 |
Why?
|
| Mice, Nude | 49 | 2021 | 4329 | 1.020 |
Why?
|
| Transglutaminases | 5 | 2008 | 99 | 0.900 |
Why?
|
| Cell Line, Tumor | 67 | 2024 | 14853 | 0.850 |
Why?
|
| Xenograft Model Antitumor Assays | 31 | 2021 | 3920 | 0.740 |
Why?
|
| Drug Resistance, Neoplasm | 18 | 2021 | 5409 | 0.720 |
Why?
|
| Nanoparticles | 12 | 2018 | 585 | 0.670 |
Why?
|
| RNA Interference | 9 | 2021 | 1388 | 0.630 |
Why?
|
| Chitosan | 7 | 2022 | 85 | 0.620 |
Why?
|
| Aptamers, Nucleotide | 2 | 2016 | 58 | 0.620 |
Why?
|
| Mice | 75 | 2024 | 35608 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 29 | 2021 | 9045 | 0.600 |
Why?
|
| Animals | 90 | 2024 | 62063 | 0.580 |
Why?
|
| Cisplatin | 7 | 2019 | 2497 | 0.580 |
Why?
|
| Antineoplastic Agents | 21 | 2023 | 14623 | 0.560 |
Why?
|
| Apoptosis | 31 | 2024 | 7758 | 0.550 |
Why?
|
| Cell Proliferation | 36 | 2023 | 7239 | 0.520 |
Why?
|
| Gene Silencing | 15 | 2021 | 827 | 0.500 |
Why?
|
| Endothelial Cells | 4 | 2017 | 1038 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 13 | 2023 | 1580 | 0.460 |
Why?
|
| Uterine Neoplasms | 4 | 2021 | 576 | 0.450 |
Why?
|
| Neoplasms | 18 | 2023 | 15933 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 10 | 2023 | 1269 | 0.420 |
Why?
|
| Lymphocytes | 2 | 2021 | 1275 | 0.400 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2016 | 499 | 0.390 |
Why?
|
| Phosphatidylcholines | 4 | 2016 | 128 | 0.380 |
Why?
|
| Liposomes | 6 | 2019 | 704 | 0.380 |
Why?
|
| GTP-Binding Proteins | 5 | 2008 | 342 | 0.370 |
Why?
|
| Weightlessness | 1 | 2011 | 56 | 0.370 |
Why?
|
| Cell Survival | 14 | 2018 | 3066 | 0.370 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 427 | 0.370 |
Why?
|
| Signal Transduction | 24 | 2021 | 12108 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 840 | 0.360 |
Why?
|
| Gene Transfer Techniques | 4 | 2018 | 804 | 0.360 |
Why?
|
| Cancer-Associated Fibroblasts | 3 | 2021 | 116 | 0.330 |
Why?
|
| Extracellular Vesicles | 2 | 2021 | 134 | 0.320 |
Why?
|
| Genetic Therapy | 7 | 2018 | 1716 | 0.320 |
Why?
|
| Female | 82 | 2024 | 149107 | 0.320 |
Why?
|
| Autophagy | 4 | 2016 | 911 | 0.310 |
Why?
|
| Cation Transport Proteins | 1 | 2009 | 170 | 0.300 |
Why?
|
| RNA-Binding Proteins | 3 | 2019 | 1017 | 0.300 |
Why?
|
| RNA Editing | 2 | 2019 | 97 | 0.300 |
Why?
|
| Phosphoproteins | 3 | 2017 | 1138 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2021 | 266 | 0.290 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2018 | 57 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2023 | 1838 | 0.280 |
Why?
|
| Neoplasm Metastasis | 10 | 2019 | 5315 | 0.280 |
Why?
|
| Microtubules | 2 | 2018 | 329 | 0.280 |
Why?
|
| RNAi Therapeutics | 2 | 2018 | 44 | 0.270 |
Why?
|
| Humans | 93 | 2024 | 271010 | 0.270 |
Why?
|
| Endometrial Neoplasms | 3 | 2024 | 1387 | 0.270 |
Why?
|
| Paclitaxel | 7 | 2019 | 2101 | 0.270 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2024 | 617 | 0.270 |
Why?
|
| Carcinoma | 6 | 2013 | 2610 | 0.260 |
Why?
|
| Extracellular Matrix | 2 | 2006 | 523 | 0.260 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 1471 | 0.260 |
Why?
|
| Cell Movement | 14 | 2019 | 2474 | 0.260 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10709 | 0.250 |
Why?
|
| Peptides | 3 | 2019 | 1504 | 0.250 |
Why?
|
| Neoplasm Proteins | 6 | 2017 | 3346 | 0.240 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 806 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 11 | 2019 | 4048 | 0.240 |
Why?
|
| Piperazines | 6 | 2019 | 2145 | 0.240 |
Why?
|
| Disease Progression | 9 | 2020 | 6868 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 7 | 2024 | 2400 | 0.220 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2019 | 170 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 5 | 2019 | 1077 | 0.220 |
Why?
|
| Oligopeptides | 3 | 2010 | 450 | 0.220 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 28 | 0.220 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 485 | 0.220 |
Why?
|
| Transfection | 6 | 2021 | 3118 | 0.210 |
Why?
|
| Doxorubicin | 4 | 2019 | 3145 | 0.210 |
Why?
|
| Glycoproteins | 2 | 2017 | 779 | 0.210 |
Why?
|
| Blotting, Western | 10 | 2017 | 3588 | 0.200 |
Why?
|
| Cell Cycle | 5 | 2019 | 2137 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 3658 | 0.200 |
Why?
|
| src-Family Kinases | 3 | 2020 | 487 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2021 | 1564 | 0.200 |
Why?
|
| RNA, Long Noncoding | 2 | 2017 | 618 | 0.200 |
Why?
|
| Cell Nucleus | 3 | 2020 | 1712 | 0.200 |
Why?
|
| Tetraspanin 30 | 1 | 2021 | 14 | 0.200 |
Why?
|
| Cell Hypoxia | 4 | 2016 | 353 | 0.200 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 4134 | 0.190 |
Why?
|
| Phthalazines | 4 | 2019 | 262 | 0.190 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2014 | 163 | 0.190 |
Why?
|
| Up-Regulation | 5 | 2019 | 2423 | 0.190 |
Why?
|
| Tumor Microenvironment | 6 | 2018 | 3035 | 0.180 |
Why?
|
| Paxillin | 1 | 2020 | 32 | 0.180 |
Why?
|
| Ribonuclease III | 3 | 2018 | 182 | 0.180 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 109 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 1281 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2022 | 303 | 0.180 |
Why?
|
| Bone Resorption | 2 | 2018 | 137 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2018 | 256 | 0.170 |
Why?
|
| Oncostatin M | 1 | 2019 | 21 | 0.170 |
Why?
|
| DNA Damage | 3 | 2019 | 1991 | 0.170 |
Why?
|
| Disease Models, Animal | 12 | 2022 | 7389 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 2 | 2021 | 885 | 0.170 |
Why?
|
| Colitis | 1 | 2023 | 341 | 0.170 |
Why?
|
| Gene Regulatory Networks | 3 | 2019 | 680 | 0.170 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 133 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2019 | 1903 | 0.170 |
Why?
|
| Norepinephrine | 2 | 2018 | 283 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2018 | 659 | 0.160 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2019 | 11 | 0.160 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 7665 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 383 | 0.160 |
Why?
|
| Breast Neoplasms | 6 | 2017 | 16216 | 0.160 |
Why?
|
| Tissue Distribution | 1 | 2021 | 929 | 0.160 |
Why?
|
| Receptors, LHRH | 1 | 2019 | 39 | 0.160 |
Why?
|
| Bevacizumab | 6 | 2023 | 967 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2017 | 6257 | 0.160 |
Why?
|
| Hemangiosarcoma | 1 | 2021 | 238 | 0.160 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2018 | 21 | 0.150 |
Why?
|
| Transcriptional Activation | 2 | 2019 | 1111 | 0.150 |
Why?
|
| Interferon-beta | 1 | 2018 | 109 | 0.150 |
Why?
|
| Models, Biological | 7 | 2019 | 3198 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 5759 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2015 | 3604 | 0.150 |
Why?
|
| Gonanes | 1 | 2017 | 50 | 0.150 |
Why?
|
| Tubulin Modulators | 1 | 2018 | 65 | 0.150 |
Why?
|
| Transcription Factors | 5 | 2019 | 5442 | 0.150 |
Why?
|
| Peroxisomes | 1 | 2017 | 42 | 0.150 |
Why?
|
| Dasatinib | 1 | 2021 | 881 | 0.150 |
Why?
|
| LIM Domain Proteins | 1 | 2017 | 103 | 0.150 |
Why?
|
| Integrins | 3 | 2017 | 275 | 0.150 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 191 | 0.150 |
Why?
|
| eIF-2 Kinase | 1 | 2018 | 166 | 0.140 |
Why?
|
| Anoikis | 1 | 2017 | 63 | 0.140 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2016 | 116 | 0.140 |
Why?
|
| Drug Delivery Systems | 4 | 2023 | 661 | 0.140 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2016 | 18 | 0.140 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 168 | 0.140 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 135 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2018 | 272 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2019 | 520 | 0.140 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2016 | 43 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 537 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 2073 | 0.130 |
Why?
|
| Neurons | 2 | 2017 | 2454 | 0.130 |
Why?
|
| Immunoconjugates | 2 | 2010 | 314 | 0.130 |
Why?
|
| Genes, myc | 1 | 2017 | 372 | 0.130 |
Why?
|
| Amino Acid Transport Systems | 1 | 2015 | 16 | 0.130 |
Why?
|
| Blood Platelets | 2 | 2017 | 677 | 0.130 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2014 | 162 | 0.130 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2016 | 85 | 0.130 |
Why?
|
| Tumor Burden | 5 | 2017 | 2034 | 0.130 |
Why?
|
| Aspartic Acid | 1 | 2016 | 136 | 0.130 |
Why?
|
| Acetyltransferases | 1 | 2016 | 146 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 530 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2017 | 361 | 0.130 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 1554 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 1 | 2017 | 522 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 2013 | 102 | 0.120 |
Why?
|
| Macrophages | 2 | 2022 | 1352 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 16689 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 442 | 0.120 |
Why?
|
| Troponin C | 1 | 2014 | 24 | 0.120 |
Why?
|
| Taxoids | 3 | 2014 | 1015 | 0.120 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 125 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 241 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 7 | 2023 | 4481 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2019 | 1419 | 0.120 |
Why?
|
| Contractile Proteins | 1 | 2014 | 44 | 0.120 |
Why?
|
| Folate Receptor 1 | 1 | 2014 | 61 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 345 | 0.120 |
Why?
|
| Erythropoietin | 1 | 2015 | 224 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 742 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2018 | 903 | 0.110 |
Why?
|
| Transplantation, Heterologous | 6 | 2017 | 1054 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 380 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 195 | 0.110 |
Why?
|
| Omentum | 1 | 2014 | 108 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1042 | 0.110 |
Why?
|
| Receptors, Progesterone | 2 | 2017 | 1604 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1193 | 0.110 |
Why?
|
| Pericytes | 2 | 2013 | 91 | 0.110 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 385 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2014 | 155 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 4962 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 107 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 1126 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 754 | 0.110 |
Why?
|
| Hypertension | 1 | 2022 | 1592 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2021 | 2767 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2017 | 1121 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2665 | 0.100 |
Why?
|
| Glutamine | 1 | 2014 | 325 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2014 | 232 | 0.100 |
Why?
|
| Ovary | 1 | 2016 | 688 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2016 | 511 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 247 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2014 | 2092 | 0.100 |
Why?
|
| Heptanoic Acids | 1 | 2012 | 89 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 317 | 0.090 |
Why?
|
| Stress, Physiological | 2 | 2013 | 493 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2024 | 1711 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1149 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2014 | 372 | 0.090 |
Why?
|
| Fluorescent Dyes | 2 | 2013 | 469 | 0.090 |
Why?
|
| Binding Sites | 2 | 2019 | 2256 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 127 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2009 | 1045 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2016 | 695 | 0.090 |
Why?
|
| Silicon | 1 | 2010 | 48 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2018 | 7104 | 0.090 |
Why?
|
| HEK293 Cells | 3 | 2019 | 1462 | 0.090 |
Why?
|
| Immunoprecipitation | 5 | 2009 | 589 | 0.090 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 5151 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 1582 | 0.090 |
Why?
|
| Cell Adhesion | 3 | 2009 | 1028 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2009 | 44 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2010 | 77 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2453 | 0.090 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 46 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 517 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1958 | 0.080 |
Why?
|
| Copper-transporting ATPases | 1 | 2009 | 44 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 637 | 0.080 |
Why?
|
| Dopamine | 1 | 2011 | 333 | 0.080 |
Why?
|
| Estrous Cycle | 1 | 2009 | 40 | 0.080 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 1389 | 0.080 |
Why?
|
| Pyrimidinones | 2 | 2021 | 318 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 2474 | 0.080 |
Why?
|
| Prostatic Neoplasms | 3 | 2017 | 5867 | 0.080 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Protein Binding | 3 | 2015 | 3485 | 0.080 |
Why?
|
| Pyrimidines | 3 | 2016 | 3671 | 0.080 |
Why?
|
| Topotecan | 1 | 2009 | 248 | 0.080 |
Why?
|
| Phosphorylation | 4 | 2018 | 4945 | 0.080 |
Why?
|
| Pyridones | 2 | 2021 | 360 | 0.080 |
Why?
|
| Catalysis | 2 | 2006 | 245 | 0.080 |
Why?
|
| Fibronectins | 2 | 2006 | 205 | 0.080 |
Why?
|
| DNA Adducts | 1 | 2009 | 214 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 639 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 4 | 2010 | 438 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2023 | 606 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 998 | 0.080 |
Why?
|
| Neuropilin-2 | 1 | 2008 | 21 | 0.080 |
Why?
|
| Prognosis | 7 | 2021 | 22509 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 768 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2021 | 848 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2018 | 894 | 0.070 |
Why?
|
| Pyrroles | 1 | 2012 | 589 | 0.070 |
Why?
|
| Lymphoma | 1 | 2016 | 1520 | 0.070 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2007 | 143 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2014 | 3409 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 859 | 0.070 |
Why?
|
| Wound Healing | 2 | 2017 | 768 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2013 | 878 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 460 | 0.070 |
Why?
|
| Gene Expression | 1 | 2015 | 3643 | 0.070 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 2 | 2019 | 36 | 0.070 |
Why?
|
| Fibrosis | 2 | 2022 | 733 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2008 | 191 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 1823 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2009 | 1946 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 2618 | 0.070 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 3707 | 0.070 |
Why?
|
| Recombinational DNA Repair | 2 | 2017 | 79 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2014 | 1718 | 0.070 |
Why?
|
| alpha Karyopherins | 1 | 2006 | 13 | 0.070 |
Why?
|
| HCT116 Cells | 3 | 2013 | 354 | 0.070 |
Why?
|
| beta-Glucosidase | 1 | 2005 | 5 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2005 | 58 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2005 | 51 | 0.060 |
Why?
|
| Agrobacterium tumefaciens | 1 | 2005 | 8 | 0.060 |
Why?
|
| Estradiol | 1 | 2009 | 828 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 484 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 168 | 0.060 |
Why?
|
| Cytosol | 1 | 2006 | 267 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2016 | 1003 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2019 | 5698 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2006 | 167 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 4821 | 0.060 |
Why?
|
| Estrogens | 1 | 2009 | 809 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2017 | 548 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2006 | 168 | 0.060 |
Why?
|
| Cyclic AMP | 2 | 2018 | 378 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 318 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 258 | 0.060 |
Why?
|
| Phenotype | 2 | 2006 | 6517 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2010 | 904 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2021 | 5731 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 5071 | 0.060 |
Why?
|
| Protein Folding | 1 | 2005 | 297 | 0.060 |
Why?
|
| Streptomyces | 1 | 2003 | 22 | 0.060 |
Why?
|
| Receptors, Scavenger | 1 | 2023 | 8 | 0.060 |
Why?
|
| Polymethacrylic Acids | 1 | 2023 | 10 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2006 | 339 | 0.060 |
Why?
|
| Cell Line | 1 | 2011 | 5339 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 2 | 2017 | 545 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10265 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4117 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2010 | 1189 | 0.050 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2022 | 7 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 2175 | 0.050 |
Why?
|
| Thiolester Hydrolases | 1 | 2022 | 36 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 2 | 2016 | 273 | 0.050 |
Why?
|
| Receptors, CCR2 | 1 | 2022 | 44 | 0.050 |
Why?
|
| Stromal Cells | 2 | 2016 | 826 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2022 | 563 | 0.050 |
Why?
|
| Rats | 3 | 2017 | 6526 | 0.050 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 7916 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2022 | 198 | 0.050 |
Why?
|
| Endocytosis | 2 | 2014 | 233 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 1136 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2013 | 336 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2021 | 155 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2014 | 264 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4958 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 1050 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 622 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5593 | 0.040 |
Why?
|
| Survival Rate | 3 | 2020 | 12542 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 34 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2005 | 1309 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 161 | 0.040 |
Why?
|
| Organ Size | 2 | 2014 | 692 | 0.040 |
Why?
|
| Transcriptome | 2 | 2021 | 1962 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2023 | 1610 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 317 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2009 | 199 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 4224 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 88 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2015 | 784 | 0.040 |
Why?
|
| Receptor, trkB | 1 | 2018 | 52 | 0.040 |
Why?
|
| Genes, MDR | 1 | 2018 | 43 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2013 | 1811 | 0.040 |
Why?
|
| Ki-67 Antigen | 2 | 2011 | 676 | 0.040 |
Why?
|
| Microvessels | 2 | 2009 | 145 | 0.040 |
Why?
|
| Focal Adhesions | 1 | 2017 | 44 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 1642 | 0.040 |
Why?
|
| U937 Cells | 1 | 2017 | 178 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2018 | 160 | 0.040 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2017 | 21 | 0.040 |
Why?
|
| Receptor, TIE-2 | 1 | 2017 | 78 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2017 | 43 | 0.040 |
Why?
|
| Permeability | 1 | 2017 | 160 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2017 | 255 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 1092 | 0.040 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2017 | 88 | 0.040 |
Why?
|
| Inosine | 1 | 2017 | 42 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2018 | 141 | 0.040 |
Why?
|
| Microcirculation | 1 | 2017 | 190 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2017 | 132 | 0.040 |
Why?
|
| Frontal Lobe | 1 | 2017 | 167 | 0.040 |
Why?
|
| Sequestosome-1 Protein | 1 | 2016 | 39 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2018 | 163 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2018 | 232 | 0.030 |
Why?
|
| Biomarkers | 2 | 2019 | 5063 | 0.030 |
Why?
|
| Autophagosomes | 1 | 2016 | 40 | 0.030 |
Why?
|
| Polyphosphates | 1 | 2017 | 16 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2017 | 285 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2016 | 55 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 344 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2019 | 589 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 147 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2016 | 52 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 92 | 0.030 |
Why?
|
| Lipid Droplets | 1 | 2016 | 56 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2017 | 167 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 101 | 0.030 |
Why?
|
| Nitrogen | 1 | 2016 | 181 | 0.030 |
Why?
|
| Nucleotides | 1 | 2016 | 174 | 0.030 |
Why?
|
| Quinazolines | 1 | 2021 | 956 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2017 | 33774 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 322 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 100 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 628 | 0.030 |
Why?
|
| Base Sequence | 2 | 2014 | 5437 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 528 | 0.030 |
Why?
|
| Carbon | 1 | 2016 | 165 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2018 | 397 | 0.030 |
Why?
|
| Receptors, Erythropoietin | 1 | 2015 | 76 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2008 | 895 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 659 | 0.030 |
Why?
|
| Smoking | 1 | 2005 | 2555 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 314 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 384 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 230 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2003 | 2100 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 217 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1710 | 0.030 |
Why?
|
| Adenosine | 1 | 2017 | 296 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 136 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2017 | 242 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 572 | 0.030 |
Why?
|
| Parabiosis | 1 | 2014 | 14 | 0.030 |
Why?
|
| Monocytes | 1 | 2018 | 790 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 327 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2014 | 15 | 0.030 |
Why?
|
| Adipocytes | 1 | 2016 | 299 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 678 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 274 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 195 | 0.030 |
Why?
|
| Receptor, Notch3 | 1 | 2014 | 39 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 590 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2014 | 85 | 0.030 |
Why?
|
| Neuregulin-1 | 1 | 2014 | 89 | 0.030 |
Why?
|
| Indazoles | 1 | 2016 | 310 | 0.030 |
Why?
|
| Middle Aged | 5 | 2021 | 90433 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 2116 | 0.030 |
Why?
|
| Dynamins | 1 | 2014 | 75 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2014 | 103 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 739 | 0.030 |
Why?
|
| Receptor, ErbB-3 | 1 | 2014 | 126 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 355 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2018 | 1140 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 402 | 0.030 |
Why?
|
| R-SNARE Proteins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 926 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 606 | 0.030 |
Why?
|
| Qa-SNARE Proteins | 1 | 2013 | 41 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 757 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 784 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1033 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 496 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 1095 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 387 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 371 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2013 | 109 | 0.030 |
Why?
|
| Temperature | 2 | 2005 | 538 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 1006 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 151 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 1472 | 0.030 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 236 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 576 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 240 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2013 | 242 | 0.020 |
Why?
|
| RNA | 1 | 2017 | 1064 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2015 | 1685 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2015 | 1360 | 0.020 |
Why?
|
| Male | 6 | 2018 | 128533 | 0.020 |
Why?
|
| Actins | 1 | 2014 | 602 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 3341 | 0.020 |
Why?
|
| Tyrosine | 1 | 2013 | 509 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 2011 | 52 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1199 | 0.020 |
Why?
|
| Stem Cells | 1 | 2018 | 1217 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 13024 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 929 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2013 | 531 | 0.020 |
Why?
|
| Microspheres | 1 | 2011 | 238 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2012 | 751 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3217 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2311 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 3029 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 14013 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 337 | 0.020 |
Why?
|
| Histones | 1 | 2017 | 1513 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 368 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2016 | 1875 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2009 | 105 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2009 | 6398 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2015 | 1624 | 0.020 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2009 | 27 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 1474 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 1427 | 0.020 |
Why?
|
| DNA Repair | 1 | 2017 | 1910 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 1125 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 154 | 0.020 |
Why?
|
| Propranolol | 1 | 2009 | 158 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 1589 | 0.020 |
Why?
|
| Caspases | 1 | 2011 | 679 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2008 | 193 | 0.020 |
Why?
|
| Cardiotoxins | 1 | 2007 | 16 | 0.020 |
Why?
|
| Semaphorins | 1 | 2008 | 37 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1496 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 396 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 121 | 0.020 |
Why?
|
| K562 Cells | 1 | 2007 | 345 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 214 | 0.020 |
Why?
|
| Terbutaline | 1 | 2006 | 30 | 0.020 |
Why?
|
| Integrin alpha4 | 1 | 2006 | 26 | 0.020 |
Why?
|
| Integrin alpha5 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2016 | 1933 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2006 | 80 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2006 | 134 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2006 | 37 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2009 | 669 | 0.020 |
Why?
|
| Aged | 3 | 2021 | 73460 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2010 | 673 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2006 | 259 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 562 | 0.020 |
Why?
|
| Protein Renaturation | 1 | 2005 | 6 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 2655 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2006 | 128 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2005 | 72 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 879 | 0.020 |
Why?
|
| Alcohols | 1 | 2005 | 24 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2005 | 110 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2005 | 159 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 741 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2005 | 721 | 0.010 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 692 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 634 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 2058 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2346 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 581 | 0.010 |
Why?
|
| Xylan Endo-1,3-beta-Xylosidase | 1 | 2003 | 1 | 0.010 |
Why?
|
| Mutation | 2 | 2018 | 15915 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 1525 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2932 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1691 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2003 | 237 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 31050 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 936 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2212 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2320 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2005 | 1255 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2008 | 3045 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1879 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2007 | 1144 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 2221 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 1988 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2007 | 724 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9294 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 15231 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 13424 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2014 | 3557 | 0.010 |
Why?
|
| Cytokines | 1 | 2009 | 2826 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 5779 | 0.010 |
Why?
|
| Pyridines | 1 | 2006 | 1313 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 9040 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 4895 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 22260 | 0.010 |
Why?
|
| Adult | 2 | 2015 | 82090 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 12033 | 0.010 |
Why?
|